Interações medicamentosas entre “kit covid” e medicamentos de uso crônico

Abstract

Since the beginning of the pandemic, drugs with antiviral activity, such as chloroquine and hydroxychloroquine, have been recommended in some countries as drug therapy against SARS CoV 2, which in Brazil has been called the "covid kit". Objective: D escribe the drug interactions of the drugs that are part of the "Covid Kit", prioritizing those contained in the Ministry of Health's early drug handling information note, with the main drugs used in the treatment of chronic diseases in Brazil. Method : An integra tive literature review was carried out in order to gather evidence, based on empirical and current analysis, on the risks associated with drug interactions. Results : Of the 23 articles selected, read in full and supplemented with information from Drugs.com, Hydroxychloroquine had 39 interactions, followed by Azithromycin with 22 interactions and Ivermectin with 8 interactions . The risk of drug interaction involving these drugs is most often pharmacodynamic in nature, associated with prolongation of the QT i nterval, the severity of which can cause cardiac arrhythmias depending on the associated drug, ranging from moderate to severe. Conclusion : The drugs in the "Covid Kit" interact substantially with drugs used in chronic diseases, with the most frequent interactions being with Hydroxychloroquine/Chloroquine, associated with cardiac arrhythmias due to prolongation of the QT interval